Effectiveness of Subcutaneous Anifrolumab in Systemic Lupus Erythematodes - A Non-interventional, Prospective, Multicenter Study on Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care
Latest Information Update: 25 Feb 2026
At a glance
- Drugs Anifrolumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Acronyms VIOLET
- Sponsors AstraZeneca
Most Recent Events
- 25 Feb 2026 New trial record